MedTrace Logo

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

NCT01341301 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-04-30

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to examine the survival of patients undergoing partially matched hematopoietic stem cell transplant (HSCT) on a new type of treatment approach, which has been developed specifically for patients who have evidence of their disease at the time of transplant. In this research study, a way of strengthening the response of the donor cells against the disease has been developed. Patients will undergo one additional day between the two steps of the transplant which may allow their donor's cells to fight the disease more effectively.

Conditions

  • Hematologic Malignancy

Interventions

RADIATION

Total Body Irradiation

Undergo TBI

BIOLOGICAL

Donor Lymphocyte Infusion (DLI)

Undergo DLI

DRUG

Cyclophosphamide

Given IV

DRUG

Tacrolimus

Given IV or PO

DRUG

Mycophenolate mofetil

Given IV or PO

PROCEDURE

Allogeneic hematopoietic stem cell transplantation

Undergo allogeneic HSCT

OTHER

Laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    lead OTHER

Principal Investigators

  • Neal Flomenberg, MD · Thomas Jefferson University

  • Dolores Grosso, DNP, CRNP · Thomas Jefferson University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2013-11-04
Completion
2014-08-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01341301 on ClinicalTrials.gov